POPULARITY
24 episodes with Adjuvant
14 episodes with Adjuvant
23 episodes with Adjuvant
11 episodes with Adjuvant
10 episodes with Adjuvant
26 episodes with Adjuvant
11 episodes with Adjuvant
27 episodes with Adjuvant
30 episodes with Adjuvant
11 episodes with Adjuvant
4 episodes with Adjuvant
10 episodes with Adjuvant
9 episodes with Adjuvant
11 episodes with Adjuvant
26 episodes with Adjuvant
4 episodes with Adjuvant
7 episodes with Adjuvant
4 episodes with Adjuvant
8 episodes with Adjuvant
6 episodes with Adjuvant
6 episodes with Adjuvant
5 episodes with Adjuvant
4 episodes with Adjuvant
9 episodes with Adjuvant
6 episodes with Adjuvant
4 episodes with Adjuvant
5 episodes with Adjuvant
3 episodes with Adjuvant
5 episodes with Adjuvant
6 episodes with Adjuvant
2 episodes with Adjuvant
3 episodes with Adjuvant
3 episodes with Adjuvant
4 episodes with Adjuvant
3 episodes with Adjuvant
8 episodes with Adjuvant
Does Senital Node Biopsy improve survival in melanoma patients?Co-treating Ixekizumab With Tirzepatide - does it enhance response?Adjuvant cemiplimab in high-risk SCC, does it help?Do we need to do CXR before starting methotrexate?How effective are systemics at controlling generalised pustular psoriasis?Stage IIC vs IIIA melanoma survival analysis
General Principles and Triple AssessmentThe foundation of breast cancer diagnosis is the Triple Assessment protocol, which includes clinical examination, imaging, and pathological assessment.Diagnostic accuracy reaches 99.9% when all three modalities of the Triple Assessment align.Imaging choices are age-dependent, with ultrasound preferred for women under 35 and mammography for those over 35.Core needle biopsy is superior to fine-needle aspiration because it differentiates between in situ and invasive disease and allows for hormone receptor and HER2 status testing.The majority of breast cancers are sporadic, accounting for 65% to 75% of cases, while hereditary factors like BRCA 1 and 2 mutations contribute to 5% to 10%.Classification and Clinical PresentationBreast cancer is classified into non-invasive types, such as Ductal Carcinoma In Situ (DCIS), and invasive types, of which invasive ductal carcinoma is the most common.The most frequent clinical presentation is a hard, irregular, non-tender, and poorly mobile palpable mass.Approximately 60% of breast tumors are located in the upper outer quadrant.Advanced clinical features include skin dimpling from Cooper's ligament involvement, nipple retraction, and peau d'orange due to lymphatic obstruction.Paget's disease of the nipple presents as a unilateral, eczema-like ulceration and is often associated with an underlying malignancy.Staging and PrognosisClinical staging follows the TNM system, assessing the primary tumor size (T), regional lymph node involvement (N), and distant metastasis (M).Stage I and II are classified as early breast cancer, Stage III as locally advanced, and Stage IV as metastatic disease.The Nottingham Prognostic Index (NPI) calculates prognosis based on tumor size, nodal status, and histological grade.Five-year survival rates decrease significantly with advancing stage, from 90% in Stage I to 20% in Stage IV.Management of DCIS and Early Breast Cancer (Stages I & II)DCIS is a non-invasive cancer confined by an intact basement membrane that requires treatment to prevent progression to invasive disease.Standard treatment for DCIS is breast-conserving surgery (BCS) followed by radiation, or a mastectomy if the disease is widespread.For early invasive cancer, BCS followed by radiation is oncologically equivalent to a total mastectomy.Sentinel lymph node biopsy (SLNB) is the standard for staging the axilla in clinically node-negative patients to avoid the morbidity of full axillary dissection.Adjuvant systemic therapy, including endocrine therapy for ER-positive tumors and anti-HER2 therapy for HER2-positive tumors, is dictated by the tumor's biological profile.Management of Locally Advanced (Stage III) and Metastatic Cancer (Stage IV)Locally advanced breast cancer is treated with neoadjuvant systemic therapy as the first step to shrink the tumor and treat micrometastatic disease before surgery.Following neoadjuvant therapy, axillary lymph node dissection is mandatory if nodes were positive at presentation, regardless of the clinical response.Post-mastectomy radiation is indicated for tumors larger than 5 cm or when four or more axillary nodes are positive.Metastatic (Stage IV) disease is treatable but generally incurable, focusing on palliation and maintaining quality of life.Systemic therapy is the mainstay for Stage IV, and routine surgery on the primary tumor is avoided unless needed for local symptom control.Bone is the most common site of metastasis, requiring management with bone-modifying agents like bisphosphonates to prevent skeletal complicatio
The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma 2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved for AML. 3. Zenoctuzumab gets an FDA approval for cholangiocarcinoma with an efficacy patient population = 19 4. T-DXd is a good drug and continues to pile on FDA approvals 5. Adjuvant atezolizumab in bladder cancer is approved in conjunction with ctDNA serial monitoring to determine who gets treatment Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.
Guest Dr. Glenwood Goss discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT
BUFFALO, NY – May 13, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case report and literature review.” The study was led by first author Bolat Shalabaev and corresponding author Zhuldyz Kuanysh, both from the National Research Oncology Center, Astana, Kazakhstan. In this report, the authors describe a rare case of high-grade laryngeal leiomyosarcoma (LLMS) in a 64-year-old man who presented with progressive dyspnea and hoarseness caused by a large supraglottic mass. Laryngeal leiomyosarcoma is an exceptionally uncommon malignant tumor of smooth muscle origin, with fewer than 70 cases reported worldwide since it was first described in 1939. Because most laryngeal malignancies are epithelial tumors such as squamous cell carcinoma, diagnosis of LLMS can be particularly challenging and requires extensive histopathological and immunohistochemical evaluation. Imaging studies revealed a heterogeneous laryngeal tumor causing near-complete obstruction of the airway. Histopathological analysis demonstrated high-grade spindle-cell proliferation with marked pleomorphism and pathological mitoses. Immunohistochemical testing showed strong expression of smooth muscle actin (SMA) and vimentin, while markers including CD34, myogenin, cytokeratins 5/6 and 7, and p40 were negative, supporting the diagnosis of high-grade pleomorphic leiomyosarcoma. The patient underwent extended laryngectomy with left neck dissection and formation of a permanent tracheostomy. Comprehensive staging with CT, MRI, and ultrasound showed no evidence of regional or distant metastases. Due to the tumor's aggressive pathological features—including a Ki-67 proliferation index reaching 60%—the multidisciplinary tumor board recommended adjuvant chemotherapy with doxorubicin and ifosfamide following surgery. “Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients.” Postoperative pathology confirmed a high-grade pleomorphic leiomyosarcoma classified as pT3N0M0 according to the AJCC 8th edition staging system. Importantly, surgical margins were negative, and no metastatic involvement was identified in the five examined lymph nodes. At the most recent follow-up, 12 months after surgery and completion of chemotherapy, the patient remained alive and free of recurrence or metastasis. The authors also reviewed recently published LLMS cases reported between 2021 and 2024. Their analysis confirmed persistent male predominance, frequent involvement of the glottic and supraglottic regions, and highly variable clinical outcomes ranging from long-term disease-free survival to rapid metastatic progression. The report further highlights the central role of immunohistochemistry in differentiating leiomyosarcoma from other spindle-cell neoplasms of the head and neck. Importantly, the study emphasizes that complete surgical resection with histologically negative margins remains the most important factor associated with favorable outcomes. While the role of chemotherapy in laryngeal leiomyosarcoma remains controversial, the authors note that individualized multidisciplinary treatment approaches may be particularly valuable in patients with high-grade or high-risk disease features. Overall, this report contributes important clinical insight into one of the rarest malignancies of the larynx. As the first documented case of laryngeal leiomyosarcoma reported from Central Asia, the study expands the limited global literature on this disease and underscores the importance of coordinated multidisciplinary care, detailed pathological evaluation, and long-term surveillance in optimizing patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28862 Correspondence to - Zhuldyz Kuanysh - zhuldyzkuanysh@icloud.com Abstract video - https://www.youtube.com/watch?v=i3AoqIXo3Ys
Send us Fan MailJoin us as we complete our tour of the adjuvant kidney cancer treatment space.We are joined again by the excellent Dr Will Ince from Cambridge and Dr Naveen Vasudev from Leeds!In our last episode we discussed KEYNOTE 564 and the RAMPART study and where this places immunotherapy in adjuvant kidney cancer.In this episode we discuss the LITESPARK 022 trial and the addition of Belzutifan to Pembrolizumab in adjuvant kidney cancer treatment.We also discuss the potential for KIM-1 to be used as a biomarker to highlight those higher risk patients that may benefit from adjuvant immunotherapy.This is an exciting time for adjuvant treatment in kidney cancer.All this as Will continues to misbehave to amuse himself!!We hope you enjoy!
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Guru P. Sonpavde, MD What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their discussion highlights how ctDNA monitoring identifies early recurrence risk, captures real-time immunotherapy activity, and positions ctDNA clearance as a powerful prognostic marker. Dr. Sonpavde is the Medical Director of Genitourinary Oncology and the Phase I Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando.
In this podcast, experts Ann H. Partridge, MD, MPH; Saranya Chumsri, MD; and William J. Gradishar, MD, FASCO, FACP, discuss the roles of adjuvant chemotherapy and CDK4/6 inhibitors and neoadjuvant checkpoint inhibitors for patients with early-stage, hormone receptor–positive breast cancer.
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00) Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08) Role of ctDNA in adjuvant treatment planning for Stage III colon cancer (12:31) CME information and select publications
BUFFALO, NY – April 7, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.” Led by first author Maryam Aleid from Imam Abdulrahman Bin Faisal University, and corresponding author Dhai Almuteri from King Fahad Specialist Hospital, the researchers evaluated 13 randomized controlled trials involving 9,850 patients to assess the efficacy and safety of PD-1 and PD-L1 inhibitors as adjuvant therapy following tumor resection. The analysis demonstrated that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies. The study also identified a reduction in recurrence and metastasis risk, supporting the role of these therapies in early-stage cancer management. At the same time, variability across tumor types suggests that benefits may differ depending on cancer subtype and patient population. “Adjuvant PD-1 and PD-L1 inhibitors improve disease-free and distant metastasis-free survival in selected patients with high-risk solid tumors.” In terms of safety, the findings highlight an increased incidence of adverse events associated with PD-1/PD-L1 inhibitors, including fatigue, nausea, pruritus, and hypothyroidism, emphasizing the importance of careful monitoring during treatment. The authors conclude that while PD-1/PD-L1 inhibitors offer meaningful benefits in reducing recurrence and metastasis in high-risk solid tumors, the clinical benefit must be balanced against higher toxicity rates. Future research is needed to refine patient selection, evaluate long-term survival outcomes, and better understand differences across tumor types to optimize the use of these therapies in clinical practice. DOI - https://doi.org/10.18632/oncotarget.28855 Correspondence to - Dhai Almuteri - d.almuteri@qu.edu.sa Abstract video - https://www.youtube.com/watch?v=4Ce07bHfjB4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28855 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PD-1, PD-L1, adjuvant immunotherapy, solid tumor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BRB865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2027.Raising the Bar for Survival in High-Risk HR+, HER2- EBC: A Practical Framework for the Adjuvant Setting; Real-World Strategies to Improve Risk Assessment, Candidate Identification, Differentiated CDK4/6i + ET Selection, and Optimal Treatment Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BRB865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2027.Raising the Bar for Survival in High-Risk HR+, HER2- EBC: A Practical Framework for the Adjuvant Setting; Real-World Strategies to Improve Risk Assessment, Candidate Identification, Differentiated CDK4/6i + ET Selection, and Optimal Treatment Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BRB865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2027.Raising the Bar for Survival in High-Risk HR+, HER2- EBC: A Practical Framework for the Adjuvant Setting; Real-World Strategies to Improve Risk Assessment, Candidate Identification, Differentiated CDK4/6i + ET Selection, and Optimal Treatment Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BRB865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2027.Raising the Bar for Survival in High-Risk HR+, HER2- EBC: A Practical Framework for the Adjuvant Setting; Real-World Strategies to Improve Risk Assessment, Candidate Identification, Differentiated CDK4/6i + ET Selection, and Optimal Treatment Delivery In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
On this episode of the PAIN POD, Mark Pain Guy Garofoli chats through the complexities of adjuvant pain medications including antidepressant and other medications from other medical condition treatment plans that overlap in mechanism with pain. Join the discussion right here, right now, on the Pain Pod. Come one, come all, to the Pain Pod!!!
On this episode of the PAIN POD, Mark Pain Guy Garofoli chats through the complexities of adjuvant pain medications including antidepressant and other medications from other medical condition treatment plans that overlap in mechanism with pain. Join the discussion right here, right now, on the Pain Pod. Come one, come all, to the Pain Pod!!!
In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making. Presenters: Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health Memorial Hermann Cancer Center Professor Texas Southern University College of Pharmacy and Health Sciences Clinical Adjunct Professor McGovern Medical School Houston, Texas Julia L. Ziegengeist, PharmD, BCOP Clinical Pharmacist Specialist, Breast Medical Oncology Levine Cancer, Atrium Health Charlotte, North Carolina Link to full program:https://bit.ly/46SPGlU Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this new episode of Speaking of SurgOnc, Dr. Rick Greene & Dr. Jamie Rand discuss the article: Omission of Axillary Lymph Node Dissection in Patients with pT0-2 ER+/HER2− Breast Cancer with 3–5 Positive Lymph Nodes Undergoing Adjuvant Systemic Therapy and Radiation Does Not Impact Overall Survival: A Cancer Database Analysis, from the February 2026 issue of the Annals of Surgical Oncology.
In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Prof. Jose Karam on the results of the LITESPARK-022 study: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomised phase 3 LITESPARK-022 study.The LITESPARK-022 study will be also presented and discussed at the upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study.This interview was recorded at ASCO GU26. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of Belzutifan combined with Pembrolizumab, mechanistic insights, biomarker development, and future research directions.
Welcome to Episode 6 of our monthly GU Cast Journal Club! Two important papers in upper tract urothelial cancer (the POUT trial of adjuvant chemo post nephro-ureterectomy), and metastatic testicular cancer (the SEMS trial of surgery for early metastatic seminoma). We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. No prostate cancer today, and go easy on Declan he is struggling with man flu!Links to papers below:1. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Lancet 20202. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy J Clin Oncol 2023GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
Host: Brian P. McDonough, MD, FAAFP Guest: Matthew Galsky, MD Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky as they review the CheckMate 274 trial's long-term data, which show sustained disease-free survival and highlight ctDNA's potential as a marker for residual disease. These findings reinforce nivolumab's role in the evolving standard of care and may support more personalized post-surgical strategies. Dr. Galsky is a Professor of Medicine and the Director of Genitourinary Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York.
Eye On Research | Session 2: Adjuvant Therapies – What's New Today? (And What Can You Do About It!?) Join us for Session 2 of Eye On Research, presented by A Cure In Sight
Broadcast from KSQD, Santa Cruz on 12-04-2025: Dr. Dawn opens with an experimental vaccine that prevents severe allergic reactions by targeting IgE antibodies. The vaccine could eventually replace current monoclonal antibody treatments like omalizumab that require injections every two weeks. She explains how adjuvants work in vaccines as additives that irritate the immune system enough to notice the vaccine target. Aluminum hydroxide is s common adjuvant. Modern vaccines use small pathogen fragments rather than whole organisms, requiring adjuvants to trigger adequate immune response. Dr. Dawn expresses concern about the US Advisory Committee on Immunization Practices reviewing aluminum adjuvants this week. A Danish study of over one million children finding no connection between aluminum with autism and ADHA contradicts RFK,Jr's public claims.She worries that removing aluminum could devastate vaccine effectiveness and children's health, noting that whenever vaccination rates drop, diseases like measles return to native circulation. She recounts pertussis vaccine history—when Japan stopped vaccination due to rare adverse reactions (approximately one death per million doses), they lost about 5,000 children to whooping cough in the first year. The newer acellular vaccine using pathogen fragments plus adjuvants is safer but only lasts 4-5 years versus lifetime immunity from the older whole-cell version, necessitating "cocooning" strategies where everyone contacting newborns must be recently vaccinated. Dr. Dawn describes a vaccine to prevent fentanyl from reaching the brain now starting clinical trials in the Netherlands. It pairs a fentanyl-like molecule with a carrier protein large enough to trigger antibody production. Once primed, the immune system attacks any fentanyl entering the blood, preventing highs and overdoses—potentially helping people in addiction recovery and those accidentally exposed through contaminated drugs. She reports the first documented death from alpha-gal syndrome. Alpha-gal is a meat allergy triggered by Lone Star tick bites; the tick essentially vaccinates humans against the alpha-galactosidase protein found on beef and pork. Cases have increased since 2010 as climate change expands the tick's range northward, yet a 2023 survey found 42% of doctors had never heard of the condition. Dr. Dawn highlights research from Edith Cowan University showing that blood drawn after exercise suppresses cancer cell growth when added to tumor cultures. In breast cancer survivors, plasma from high-intensity interval training or weight lifting caused cancer cells to stop growing or die; blood drawn before exercise had no effect. The key mechanism involves myokines, particularly IL-6, released by contracting muscles. A Stanford study found colon cancer survivors who exercised were 37% less likely to experience recurrence. A caller asks about pig-to-human heart transplants and mask recommendations. Dr. Dawn clarifies that newer xenotransplant pigs have more genes edited to reduce rejection compared to the 2022 case. For masking, she recommends context-dependent use—especially in public restrooms where toilet flushing aerosolizes COVID-containing particles, transportation hubs, and hospitals, noting that COVID vaccination prevents death but not infection or long COVID. She advises the same caller about spacing vaccines because adjuvant loads stack. Most vaccines can be combined safely, but she recommends against pairing COVID and Shingrix vaccines due to their heavy adjuvant content—wait at least ten days between them. She suggests inducing a sweat the night of vaccination through hot baths, saunas, or exercise to reduce adjuvant-related discomfort without diminishing antibody response. Dr. Dawn discusses seasonal affective disorder. She recommends 5,000 units of vitamin D3 and morning light exposure. She suggests that sun avoidance advice may have gone too far. A UK study of 3.36 million people found 12-15% lower mortality with greater UV exposure even accounting for skin cancer risk. A Swedish study following 30,000 women for 20 years found sun-seekers had half the mortality risk. Benefits may involve nitric oxide production lowering blood pressure, with each 1,000 km from the equator correlating with 5 mmHg higher blood pressure. Lack of bright outdoor light also contributes to childhood myopia, with rates exceeding 80% in some Asian cities. Dr. Dawn concludes with Danish microbiologists at Copenhagen's Alchemist restaurant reviving an old Bulgarian practice of fermenting milk with live red wood ants. The resulting yogurt, cheese, and ice cream contain far more beneficial microbes than commercial products, with a complex lemony acidity. Only live ants work, and wild ants may carry parasites dangerous to humans.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 20, 2026.Risk Assessment and Treatment Initiation: Successfully Jumpstarting the Adjuvant CDK4/6 Inhibitor Treatment Journey in HR+, HER2- EBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DTQ865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Nurturing Lasting Benefits of Adjuvant CDK4/6 Inhibitor Therapy in High-Risk HR+, HER2- EBC: Best Practices for Patient Education, AE Monitoring and Management, and Enhanced Adherence/Persistence In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARM865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 20, 2026.Risk Assessment and Treatment Initiation: Successfully Jumpstarting the Adjuvant CDK4/6 Inhibitor Treatment Journey in HR+, HER2- EBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DTQ865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 25, 2026.Nurturing Lasting Benefits of Adjuvant CDK4/6 Inhibitor Therapy in High-Risk HR+, HER2- EBC: Best Practices for Patient Education, AE Monitoring and Management, and Enhanced Adherence/Persistence In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
On this episode of The Agronomists, host Lyndsey Smith is joined by Dr. Jason Deveau, application technology specialist with Ontario Ministry of Agriculture, Food and Agribusiness, and Austin Anderson, adjuvant brand manager with Helena Products Group. They discuss extra options for the spray tank and why: adjuvants and add-ins, mix order and cautions, how products... Read More
In today's episode, we had the pleasure of speaking with Vishal A. Patel, MD, FAAD, FACMS, about the FDA approval of adjuvant cemiplimab-rwlc (Libtayo) for the treatment of patients with high-risk cutaneous squamous cell carcinoma (CSCC). Dr Patel is an associate professor of dermatology at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC. In our exclusive interview, Dr Patel discussed the clinical relevance of this approval, key details about the pivotal phase 3 C-POST trial (NCT03969004), and the safety profile of cemiplimab in patients with CSCC.
In July 2023, the ACOG released a Practice Advisory stating, “Based on data on the benefit of adjunct HPV vaccination, ACOG recommends adherence to the current Centers for Disease Control and Prevention (CDC) recommendations for vaccinations of individuals aged 9–26 years, and to consider adjuvant HPV vaccination for immunocompetent previously unvaccinated people aged 27–45 years who are undergoing treatment for CIN 2+”. The possible beneficial effect of peri-treatment HPV vaccination goes back to the early 2010s. But science is always changing, and MEDICINE MOVES FAST. In September 2025, the Lancet's Obstetrics, Gynecology, and Women's Health journal published the VACCIN trial to test that guidance. These authors found that, “Although previous studies, including meta-analyses and observational studies, have shown that adjuvant HPV vaccination reduces the recurrence of cervical dysplasia after surgical treatment, our trial suggests that adjuvant HPV vaccination is not effective in reducing the recurrence of CIN 2–3 lesions, contradicting the conclusions of previous works”. They have also called for a REVISION to prior guidance. This is FASCINATING. Listen in for details. 1. ACOG PA July 2023, “Adjuvant Human Papillomavirus Vaccination for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia 2+”2. Adjuvant prophylactic human papillomavirus vaccination for prevention of recurrent high-grade cervical intraepithelial neoplasia lesions in women undergoing lesion surgical treatment (VACCIN): a multicentre, phase 4 randomised placebo-controlled trial in the Netherlands: https://www.sciencedirect.com/science/article/pii/S305050382500007X#:~:text=To%20our%20knowledge%2C%20this%20is,the%20conclusions%20of%20previous%20works.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG
Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.
At the latest ASCO-2025 meeting, Dr. Chris Booth shared the results of a study showing that adjuvant structured exercise improves overall survival in colon cancer. He joins Healthcare Unfiltered EXPRESS to detail the study, its findings, and what is next. Please share and join the conversation.
Featuring an interview with Dr Shannon N Westin, including the following topics: Biomarker testing and utility in ovarian cancer (OC) (0:00) Selection of a PARP inhibitor for the treatment of OC (9:18) Addition of immunotherapy to up-front treatment of OC (15:50) Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10) Selection of treatment for recurrent OC (21:46) Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22) Adjuvant therapy for EC (32:28) Utility of lenvatinib/pembrolizumab in EC (35:08) Clinical findings supporting the potential use of selinexor for EC (39:42) Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22) Management of adverse effects associated with T-DXd (49:49) CME information and select publications
Refresh your knowledge of testis cancer with this punchy pod with testis cancer gurus, Prof Christian Kollmannsberger (Vancouver Cancer Centre, Vancouver), and Prof Ben Tran (Peter MacCallum Cancer Centre, Melbourne). We pick their brains on three topical areas in testis cancer;1. Adjuvant chemo - balancing early gains vs late effects. How can we figure out who benefits?2. Primary RPLND - does robotic surgery change the value proposition of surgery vs chemotherapy? 3. The outstanding mi371 tumour marker - a bluffer's guideWith your usual hosts. Declan Murphy and Renu Eapen. Even better on our YouTube channel
CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations. *This program was published on July 31st, 2025 and the information therein was up-to-date when created.
CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations. *This program was published on July 31st, 2025 and the information therein was up-to-date when created.
Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant management of urothelial cancer, focussing on the sometimes contradictory data of adjuvant immunotherapy. This is an emerging area of treatment that you will not want to miss!Studies discussed in this episodeAMBASSADORCheckmate 274IMvigor010For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Show notes at pharmacyjoe.com/episode1024. In this episode, I'll discuss the use of adjuvant midodrine in patients with septic shock. The post 1024: Adjuvant Midodrine Lowers Norepinephrine Dose But Not Length of Stay in Patients With Septic Shock appeared first on Pharmacy Joe.
AABP Executive Director Dr. Fred Gingrich is joined by Dr. Chris Chase, Emeritus Professor in the Department of Veterinary and Biomedical Sciences and Dr. Curt Vlietstra, Senior Professional Services Veterinarian with Boehringer Ingelheim. This episode is sponsored by Boehringer Ingelheim, manufacturer of the Pyramid line of cattle vaccines. Find more information about Pyramid/Presponse vaccines by visiting this page. Adjuvants are a critical component of vaccines, but they can be an overlooked factor when putting together a vaccine program. The three roles of adjuvants serve in vaccines are creating a danger signal for the host, help the immune system recognize the antigen and to protect the antigen. Historically, there has been some skepticism around vaccinating young calves early due to the presence of maternal antibodies. Our guests discuss what role vaccines serve in a calf program while recognizing the importance of colostral immunity and the purpose it serves. Adjuvants can serve an important role in young calves to help with a vaccine-induced immune response. Our guests discuss the METASTIM adjuvant, how it differs from other adjuvants, and the role it plays in boosting immunity even in the face of maternal antibodies. Veterinarians play a critical role in developing vaccine programs for their clients' herds. This not only includes ensuring that the appropriate vaccines are selected for the herd, but also making sure that nutrition, specifically vitamin and mineral nutrition, is appropriate, stress is minimized, and vaccine storage and administration is correct. We close the podcast by discussing the future of vaccine and adjuvant technologies that veterinarians should be aware of and how these potential uses can improve cattle health. Veterinarians can go to https://bi-animalhealth.com/cattle/ or talk to their Boehringer Professional Services Veterinarian for more information.
Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
How do the eligibility criteria for the monarchE and NATALEE clinical trials compare? Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002403?ecd=bdc_podcast_libsyn_mscpedu
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease recurrence, as well as the rapid enrollment of this innovative study and what it means for the future of kidney cancer treatment. Read the publication in Nature. https://www.nature.com/articles/s41586-024-08507-5 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
TWiV reviews passing of Ann Palmenberg, deadly illness in western Congo, US disruption of mpox and ebolavirus programs, first measles death in Texas outbreak, flu vaccine selection meeting postponed, US withdraws from polio, malaria, HIV programs and more, clade 2.3.4.4b H5N1 viruses have a long HA stalk, and systems vaccinology to identify predictors of durable antibody response to multiple vaccines in humans. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2025 Ann Palmenberg dies (Cress) Ann at Chumakov Symposium (YouTube) Unknown illness in Congo (NY Times) Bad news about mpox outbreak (NPR) US interrupts Ebola prevention program (NPR) First measles death in Texas (Texas Trib) Flu vaccine selection meeting canceled (NY Times) US ends funding for polio, HIV, malaria and more (NY Times) Clade 2.3.4.4b H5N1 neuraminidase has a long stalk (mBio) Predictors of durable antibody responses to vaccines (Nat Immunol) Review of adjuvants (Vaccinol Methods Vacc Res) Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Video of the Northern Lights from Space Rich – Vaccination for Sudan Ebola virus disease Alan – Specialized moth wing scales give it 3-D camouflage (news and paper) Vincent – WHO Recommendations for Influenza Vaccine Composition for the 2025-2026 Northern Hemisphere Influenza Season Listener Picks Gerry – Eukaryotic Transcription Anne – The science of the solar system Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Disease (2:34) Adjuvant and Neoadjuvant Therapy (22:31) EGFR Exon 20 Insertion Mutations (34:21) Antibody-Drug Conjugates (42:45) CME information and select publications
© 2020-2026 Ivy Podcast Discovery LLC
